🇺🇸 FDA
Pipeline program

SPM 962

243-05-001

Phase 2 small_molecule completed

Quick answer

SPM 962 for Parkinson's Disease is a Phase 2 program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
Otsuka Beijing Research Institute
Indication
Parkinson's Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials